Clinical Trials

Condor Software achieves SOC 1 Type 2 Certification

Condor Software, a leading provider of clinical trial financial management nationwide, today announced that it has successfully completed a Service Organization Control (SOC) 1 Type 2 audit. The audit, conducted by Baker Tilly, an independent auditing firm, provides assurance that Condor Software’s controls related to financial reporting are appropriately designed and operating effectively.

“Achieving SOC 1 Type 2 compliance demonstrates our commitment to providing our customers with the highest level of data integrity with complete and accurate financial reporting,” said Jennifer Kyle, CEO at Condor Software. “This audit provides independent validation of our internal controls and gives our customers peace of mind knowing that they can rely on the financial data.”

SOC 1 Type 2 reports are specifically designed for service organizations that store and process customer financial data. The audit process involved a rigorous examination of Condor Software’s controls, including:

  • Logical access controls: Ensuring that only authorized personnel have access to sensitive data.
  • Data security controls: Protecting data from unauthorized access, disclosure, alteration, or destruction.
  • Business continuity controls: Ensuring that Condor Software can continue to operate and protect customer data in the event of a disaster.
  • Vendor & Third-Party Management: Ensuring the financial data input, process, calculation and financial close outputs are complete and accurate.

The successful completion of the SOC 1 Type 2 audit is a significant milestone for Condor Software and further strengthens the company’s reputation as a trusted provider of financial software solutions.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Related posts

RxPx to launch an ‘AI Clinical Buddy System’

PR Newswire

TransPerfect Life Sciences releases Trial Interactive 10.5

PR Newswire

Character Biosciences appoints New Chief Scientific Officer

Business Wire